NICE sticks by no on Celgene's Revlimid
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has released final draft guidance confirming its decision not to recommend Celgene's Revlimid (lenalidomide) for use on the NHS in patients with some myelodysplastic syndromes.